Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
Taronish D. Dubash(Harvard University), Shyamala Maheswaran(Massachusetts General Hospital), Aditya Bardia(UCLA Health), Daniel A. Haber(Howard Hughes Medical Institute), Simona Scartoni(Menarini Group (Italy)), Virginia Kaklamani(Northwestern University), Brittany A. Reeves(Harvard University), Nassir Habboubi(Ark Therapeutic (United States)), Javier Cortés(Villa Maria Hospital), Alessio Fiascarelli(Menarini Group (Italy)), A. John Iafrate(Massachusetts General Hospital), Sumit Rai(Harvard University), Joseph A. LiCausi(Harvard University), Ben S. Wittner(Broad Institute), Teeru Bihani(Lava Therapeutics (Netherlands)), Mehmet Toner(Center for Cancer Research), Philippe Aftimos(Institut Jules Bordet), Risa Burr(Harvard University), Monica Binaschi(Menarini Group (Italy)), Heike Arlt(Radius Health (United States)), Brian Chirn(Harvard University), Hitisha Patel(Radius Health (United States)), François‐Clément Bidard(Inserm)
Cited by 6
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k